Otsuka Pharmaceutical Co., Ltd. v. Lupin Ltd. et al.

This patent infringement litigation, Otsuka Pharmaceutical Co., Ltd. v. Lupin Ltd. et al., involves Japanese pharmaceutical innovator Otsuka Pharmaceutical Co., Ltd. (Otsuka) against Indian generic drug manufacturer Lupin Ltd. and its subsidiary Lupin Pharmaceuticals, Inc. (collectively, Lupin). Otsuka, a global healthcare company specializing in innovative pharmaceuticals for central nervous system, renal, and cardiovascular health, asserted U.S. Patent Nos. 8,501,730 (the '730 patent) and 8,273,735 (the '735 patent) against Lupin. Lupin, a multinational company known for its generic and branded drug formulations, sought to market generic versions of Otsuka's Jynarque® (tolvaptan) tablets, a drug indicated to slow kidney function decline in adults with autosomal dominant polycystic kidney disease (ADPKD), through Abbreviated New Drug Application (ANDA) No. 216063. The '730 patent claims highly pure tolvaptan produced by a process involving the reduction of a benzazepine compound using a hydrogenating agent in a specific molar ratio (0.25 to 1 mole). The '735 patent covers a process for preparing benzazepine compounds, including tolvaptan, which similarly involves a reduction step with a hydrogenating agent in a defined amount.

The case was heard in the U.S. District Court for the District of Delaware under Judge Richard G. Andrews, a common venue for patent, particularly Hatch-Waxman, litigation. Delaware's prominence as a patent forum increased significantly after the Supreme Court's TC Heartland decision, which limited patent venue primarily to a defendant's state of incorporation or where they have a regular and established place of business, making Delaware a frequent choice due to many companies being incorporated there. Following a bench trial, the District Court found that Lupin did not infringe either patent and that the asserted claims of the '735 patent were invalid as obvious, while the '730 patent was found not invalid.

The litigation is notable as a Hatch-Waxman dispute concerning Jynarque®, a treatment for a serious kidney disease, with Lupin's successful challenge potentially allowing for a more affordable generic option. On appeal, the Federal Circuit affirmed the District Court's judgment of non-infringement for both patents and specifically affirmed the obviousness determinations regarding the asserted claims of the '735 patent. This outcome highlights the evolving landscape of obviousness challenges in district courts, especially in a post-IPR era where the PTAB's role has shifted, placing more emphasis on district court judges as factfinders for obviousness.

Otsuka Pharmaceutical Co., Ltd. v. Lupin Ltd. et al. (Case No. 21-900-RGA) involved key legal developments and outcomes in its patent infringement litigation, culminating in a Federal Circuit affirmation of non-infringement and obviousness for one patent.

Filing & Initial Pleadings:

• Otsuka filed its initial complaint for patent infringement on June 23, 2021, asserting U.S. Patent Nos. 8,501,730 (the '730 patent) and 10,905,694 (the '694 patent) against Lupin.
• Lupin filed its answer and counterclaims on September 7, 2021, denying infringement and asserting invalidity of the '730 and '694 patents.
• Otsuka later amended its complaint to add U.S. Patent No. 8,273,735 (the '735 patent) and subsequently stipulated to dismiss claims and counterclaims related to the '694 patent.

Claim Construction (Markman) Outcomes:

• A Markman hearing was held on July 1, 2022, to construe disputed terms in the '730 and '694 patents. The court issued a memorandum opinion on claim construction on July 26, 2022.
• During claim construction, the parties disputed the meaning of "amount" in the asserted claims, particularly regarding the hydrogenating agent's quantity. The District Court determined that the claimed amount of hydrogenating agent referred to "the amount while the reaction is occurring".

Pre-trial Developments & Trial:

• Prior to trial, the parties narrowed the issues to infringement, invalidity for obviousness, and unenforceability due to inequitable conduct.
• A three-day bench trial was held from December 18 to December 20, 2023.
• At trial, the court granted Otsuka's motion for a Rule 52(c) judgment, ruling that the asserted patents were not unenforceable due to inequitable conduct, leaving only infringement and obviousness to be decided.

District Court Outcome:

• On July 31, 2024, the District Court issued its Trial Opinion.
• The court found that Lupin did not infringe the asserted claims of either the '730 or '735 patents. Specifically, for the '730 and '735 patents, Otsuka failed to prove that Lupin's process reached "practical completion" (defined as 0.05% of the ketone precursor remaining) before more than 1 molar equivalent of sodium borohydride was added.
• The court found the asserted claims of the '735 patent invalid as obvious, primarily based on the Kondo prior art reference.
• The court found the asserted claims of the '730 patent not invalid.
• A final judgment was entered on August 7, 2024, in favor of Lupin.

Appeal & Federal Circuit Outcome:

• Otsuka appealed the District Court's final judgment to the Federal Circuit (Case No. 24-2297).
• Oral arguments were scheduled for March 4, 2026.
• On May 21, 2026, the Federal Circuit affirmed the District Court's judgment.
• The Federal Circuit affirmed the non-infringement findings for both patents.
• The Federal Circuit also affirmed the District Court's determination that the asserted claims of the '735 patent were invalid for obviousness.

Parallel PTAB IPR/PGR Proceedings:

• No information about parallel PTAB IPR/PGR proceedings for the asserted patents was found in the provided search results.

I'll verify the listed articles and search for additional coverage.

Press and analysis coverage

The decision itself. The most substantive coverage came from specialist patent outlets rather than mainstream press. Patently‑O (Dennis Crouch, 2026‑05‑21) reported that a Federal Circuit panel affirmed Judge Andrews's bench‑trial judgment in Otsuka Pharm. Co. v. Lupin Ltd., No. 24‑2297 (Fed. Cir. May 21, 2026), holding that Lupin's tolvaptan ANDA process does not infringe U.S. Patent Nos. 8,273,735 and 8,501,730 and that "the asserted method claims are invalid as obvious over Kondo's 1999 small‑scale synthesis paper." It characterized the disposition as a "fact‑bound affirmance" and nonprecedential. VitalLaw's IP Law Daily (Brian Craig, 2026‑05‑26) added the panel's reasoning in more detail: no clear error in the "practical completion" claim construction or its application; Otsuka forfeited its challenge to Lupin's expert Dr. Dichtel by failing to object at trial or file a Daubert motion; and any error in the district court's treatment of secondary considerations was harmless because "weak secondary considerations generally do not overcome a strong prima facie case of obviousness." Patent Docs (2026‑06‑18) confirmed the panel composition (Judges Hughes and Cunningham, with D. Mass. Judge Burroughs sitting by designation) and reproduced the claim language on the 0.25–1 mole borohydride range.

Why outlets treated it as significant. Patently‑O's piece is explicitly a doctrinal essay built on this case rather than a case report: Crouch argued that with "Director Squires having effectively shut down inter partes review for most filers, district courts are now being asked to step up and do the §103 obviousness invalidation work," and urged bench judges to treat the PTAB's decade of final written decisions as persuasive authority — while cautioning that "the methodology travels; the conclusion does not" because the Board applies a preponderance standard and district courts apply clear and convincing evidence. That is analyst commentary well beyond the court record. IPVerse/GreyB summarized the same article in similar terms (2026‑05‑21).

Practitioner and Hatch‑Waxman trade coverage. Robins Kaplan's GENERically Speaking bulletin (2024 Q3) covered the July 31, 2024 district court opinion, explaining the "practical completion" versus "absolute completion" dispute, the finding that Otsuka failed to prove Lupin's process reached practical completion at 0.05% residual precursor, and the obviousness holding resting on motivation to reduce borohydride (cost, post‑processing, safety) plus weak nexus because Jynarque sales were driven by the API rather than the claimed method. The 2026 Q2 bulletin covered the affirmance and the panel's rejection of Dr. Roush's experiments as lacking "appropriate quality control." A longer design‑around analysis, "Practically Complete": Otsuka v. Lupin and the Chemistry of Missed Opportunity in Hatch‑Waxman Litigation (also on Mondaq), went beyond the opinions to speculate that Lupin's "at least 1.2 molar equivalents" specification was "a patent‑motivated design‑around" that had to be balanced against large‑scale chemistry constraints — an inference the courts did not adopt.

Numbers and market impact. No damages were sought or awarded; as a §271(e)(2) ANDA case the remedy was declaratory, clearing the way for Lupin's generic. The only financial figures in the coverage come from party filings and docket trackers: Otsuka's June 2026 combined petition for panel rehearing and rehearing en banc states that "with annual U.S. revenues exceeding $1 billion, JYNARQUE® is an important product for Otsuka," and Paragraph Four lists Jynarque annual sales of JPY 130.3B with the '730 patent expiring September 1, 2026, the '735 patent August 14, 2028, and the dismissed '694 patent April 7, 2030. Note a development beyond the earlier sections: Otsuka sought panel rehearing and rehearing en banc in June 2026, arguing the panel overlooked non‑experiment expert testimony independent of Lupin's Experiments 109/115.

Gaps and a flag. I found no Reuters, Bloomberg Law, Law360, Ars Technica, or mainstream coverage of this case in my searches — the reporting is confined to patent-specialist blogs, a Wolters Kluwer daily, and law-firm bulletins, and none of it mentions parallel PTAB IPRs. Of the items in the news index, only the Patently‑O piece concerns the litigation. The March 24, 2026 SNS Insider tuberculosis market release mentions Otsuka (and Lupin, in a sibling Coherent Market Insights version) only as named market participants, with no reference to the suit; the 2021 ResearchAndMarkets/Business Wire patent database and pricing releases (April 28–29, 2021) predate the June 23, 2021 complaint and cannot report on it; and I could not verify any case-specific content in the PTSD, CNS-therapeutics, or local-anesthesia releases, which appear to be syndicated market-research items swept in because Otsuka and Lupin appear in their company lists.

Contradiction with the existing summary: the top-line case description states the Federal Circuit "affirmed the non-infringement finding for 8501730, but controversially determined its asserted method claims were invalid as obvious." Per the opinion and all coverage above, the obviousness invalidity affirmed was of the '735 patent's method claims (claims 7, 8, 10); the '730 patent's product-by-process claims were found not invalid at trial, and that holding was unchallenged on appeal. The '730 analysis was a non-infringement affirmance. Also, the metadata's "terminated 2026‑05‑21" corresponds to the Federal Circuit decision date; the district court case actually terminated on August 7, 2024 (D.I. judgment), with the appeal docketed as No. 24‑2297.

Sources

• NOTE: This disposition is nonprecedential
• PATENT—Fed. Cir.: No infringement found with Lupin’s generic kidney function decline drug
• “Practically Complete”: Otsuka v. Lupin and the Chemistry of Missed Opportunity in Hatch-Waxman Litigation - Register now for your free, tailored, daily legal newsfeed service.
• Otsuka Pharm. Co., Ltd. v. Lupin Ltd.
• GENERICally Speaking: A Hatch-Waxman Litigation Bulletin 2026 Q2
• “Practically Complete”: Otsuka v. Lupin and the Chemistry of Missed Opportunity in Hatch-Waxman Litigation - ARTICLE
• Patently-O, the nation's leading patent law blog
• Activity – parryashford
• Patent | Patently-O
• Borrowing from the Board: District Court Obviousness in the Post-IPR Era
• Borrowing from the Board | District Court Obviousness in the Post-IPR Era | iptops.com
• Patently-O, the nation's leading patent law blog

In Otsuka Pharmaceutical Co., Ltd. v. Lupin Ltd. et al., the plaintiff Otsuka was represented by attorneys from Venable LLP and local counsel from Morris, Nichols, Arsht & Tunnell LLP.

Here are the details of the counsel of record representing Otsuka Pharmaceutical Co., Ltd.:

Venable LLP (New York, NY)

• John D. Murnane (Lead Counsel)
  • Focuses on patent litigation, particularly in the pharmaceutical and biotechnology sectors.
• Joshua I. Rothman (Lead Counsel)
  • Experienced in Hatch-Waxman litigation and other intellectual property disputes.
• Alicia A. Russo (Lead Counsel)
  • Specializes in patent litigation, including ANDA cases.
• Zachary L. Garrett (Lead Counsel)
  • Involved in intellectual property litigation, including patent infringement actions. He was listed on the Federal Circuit opinion affirming the District Court's judgment.
• Becky E. Steephenson (Lead Counsel)
  • Practices in intellectual property and patent litigation.
• Stephen Krachie (Lead Counsel)
  • Focuses on patent litigation, particularly in the life sciences industry.
• Camille H. Mangiaratti (Lead Counsel)
  • Experienced in patent and other complex commercial litigation.

Morris, Nichols, Arsht & Tunnell LLP (Wilmington, DE)

• Jack B. Blumenfeld (Local Counsel)
  • A prominent Delaware attorney with extensive experience in patent litigation, frequently serving as local counsel in the District of Delaware.
• Jeremy A. Tigan (Local Counsel)
  • Practices in intellectual property litigation, often acting as local counsel in Delaware patent cases.

Defendant Lupin Ltd. and Lupin Pharmaceuticals, Inc. were represented by a team of attorneys from Knobbe Martens, Richards, Layton & Finger, P.A., and Stamoulis & Weinblatt LLC.

Here are the details of the counsel of record representing Lupin:

Knobbe Martens (Washington D.C., Seattle, Irvine, CA)

• William R. Zimmerman (Lead Counsel)
  • Co-chair of Knobbe Martens' Hatch-Waxman litigation practice, with extensive experience in pharmaceutical patent cases.
• Carol Pitzel Cruz (Lead Counsel)
  • Co-chair of Knobbe Martens' Hatch-Waxman litigation practice, specializing in patent disputes related to pharmaceutical products.
• Jared C. Bunker (Lead Counsel)
  • Partner at Knobbe Martens, involved in intellectual property and patent litigation.
• Matthew Friedrichs (Associate Counsel)
  • Associate at Knobbe Martens, practicing in intellectual property and patent litigation.

Richards, Layton & Finger, P.A. (Wilmington, DE)

• Frederick L. Cottrell, III (Local Counsel)
  • A prominent Delaware attorney with experience in intellectual property litigation, frequently serving as local counsel in the District of Delaware.
• Alexandra M. Ewing (Local Counsel)
  • Practices in intellectual property litigation, often acting as local counsel in Delaware patent cases.

Stamoulis & Weinblatt LLC (Wilmington, DE)

• Stamatios Stamoulis (Of Counsel)
  • Has over 20 years of experience in intellectual property and complex commercial law matters, including patent infringement cases in the District of Delaware and other districts. He is a recognized "IP Star" by Managing Intellectual Property.
• Richard C. Weinblatt (Of Counsel)
  • Focuses on patent litigation and appellate work, with experience in patent prosecution, infringement, and validity opinions. He has been recognized as a "Rising Star" and "IP Star" for his intellectual property litigation work.
• Shekhar Vyas (Attorney)
  • Listed as an attorney with Stamoulis & Weinblatt LLC, which is regularly recognized for its patent litigation and ANDA litigation practice.